IPN60130

Phase 2Small molecule

IPN60130 is one of 4 small molecule programs targeting Fibrodysplasia Ossificans Progressiva. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fibrodysplasia Ossificans ProgressivaActive, not recruiting

Fibrodysplasia Ossificans ProgressivaPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Fibrodysplasia Ossificans Progressiva

#DrugCompanyPhaseTrials

Versed

CConrado Roberto Hoffmann Filho

Garetosmab

3 3

INCB000928

Incyte

Phase 2

1 4

IPN60130

CClementia Pharmaceuticals Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Active, not recruiting

Fibrodysplasia Ossificans Progressiva

NCT05039515

Clinical

Trials by Indication[1]

Fibrodysplasia Ossificans Progressiva1 trial

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Active, not recruiting·CClementia Pharmaceuticals Inc.·Phase 2·NCT05039515·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPN60130. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPN60130 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPN60130. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clementia Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClementia Pharmaceuticals Inc.

IPN60130

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Fibrodysplasia Ossificans Progressiva1 trial

References

Drug Info

Quick Facts

Related News